Effect of the DGAT1 inhibitor pradigastat on triglyceride and apoB48 levels in patients with familial chylomicronemia syndrome

Pharmacokinetic and pharmacodynamic drug-drug interaction assessment between pradigastat and digoxin or warfarin

(2014) Jing-He Yan et al.   JOURNAL OF CLINICAL PHARMACOLOGY

The DGAT1 inhibitor Pradigastat Decreases Chylomicron Secretion and Prevents Postprandial Triglyceride Elevation in Humans

(2013) Charles Daniel Meyers et al.   Journal of Clinical Lipidology

Medical resource use and costs associated with chylomicronemia

(2013) Daniel Gaudet et al.   JOURNAL OF MEDICAL ECONOMICS

Gene therapy for lipoprotein lipase deficiency

(2012) Daniel Gaudet et al.   CURRENT OPINION IN LIPIDOLOGY

Proof of mechanism for the DGAT1 inhibitor AZD7687: results from a first-time-in-human single-dose study

(2012) H. Denison et al.   DIABETES OBESITY & METABOLISM

Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial

(2012) D Gaudet et al.   GENE THERAPY

Effect of Alipogene Tiparvovec (AAV1-LPLS447X) on Postprandial Chylomicron Metabolism in Lipoprotein Lipase-Deficient Patients

(2012) André C. Carpentier et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Mutations inLPL,APOC2,APOA5,GPIHBP1andLMF1in patients with severe hypertriglyceridaemia

(2012) R. P. Surendran et al.   JOURNAL OF INTERNAL MEDICINE

Genetic bases of hypertriglyceridemic phenotypes

(2011) Christopher T. Johansen et al.   CURRENT OPINION IN LIPIDOLOGY

Etiology and risk of lactescent plasma and severe hypertriglyceridemia

(2010) Karine Tremblay et al.   Journal of Clinical Lipidology

Acylation of Acylglycerols by Acyl Coenzyme A:Diacylglycerol Acyltransferase 1 (DGAT1)

(2008) Dong Cheng et al.   JOURNAL OF BIOLOGICAL CHEMISTRY